Drugs / IOV-4001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05361174 | Jul 2022 → Sep 2027 expected | metastatic melanoma, non-small cell lung carcinoma | Iovance Biotherapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IOV-4001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05361174 ↗ |
| Modality | Cell therapy | “a genetically modified autologous tumor- infiltrating lymphocytes (TIL) product” NCT05361174 ↗ |
| Target | PDCD1 | “disruption of PDCD1, the gene for programmed cell death protein-1 (PD-1)” NCT05361174 ↗ |